Last Update: 2024-03-28 02:09:12
Moderna Inc. ( MRNA ) https://www.modernatx.com
United States
Historical Returns*:
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Other Earnings and Cash Flow Stats:
Moderna Inc. ( MRNA ) Net Income TTM ($MM) is -1043.00
Moderna Inc. ( MRNA ) Operating Income TTM ($MM) is 368.00
Moderna Inc. ( MRNA ) Owners' Earnings Annual ($MM) is 689.77
Moderna Inc. ( MRNA ) Current Price to Owners' Earnings ratio is 90.17
Moderna Inc. ( MRNA ) EBITDA TTM ($MM) is 883.00
Moderna Inc. ( MRNA ) EBITDA Margin is -95.35%
Capital Allocation:
Moderna Inc. ( MRNA ) has paid 0.00 dividends per share and bought back 34.0 million shares in the past 12 months
Moderna Inc. ( MRNA ) has increased its debt by 541.0 million USD in the last 12 months
Capital Structure:
Moderna Inc. ( MRNA ) Interest-bearing Debt ($MM) as of last quarter is 668
Moderna Inc. ( MRNA ) Annual Working Capital Investments ($MM) are 2095
Moderna Inc. ( MRNA ) Book Value ($MM) as of last quarter is 13854
Moderna Inc. ( MRNA ) Debt/Capital as of last quarter is 4%
Other Balance Sheet Stats:
Moderna Inc. ( MRNA ) has 2907 million in cash on hand as of last quarter
Moderna Inc. ( MRNA ) has 3015 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Moderna Inc. ( MRNA ) has 382 common shares outstanding as of last quarter
Moderna Inc. ( MRNA ) has 0 million USD of preferred stock value
Academic Scores:
Moderna Inc. ( MRNA ) Altman Z-Score is 5.93 as of last quarter
Moderna Inc. ( MRNA ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Moderna Inc. ( MRNA ) largest shareholder is owning shares at 0.00 ($MM) value
AFEYAN NOUBAR(an insider) Sold 5778 shares of Moderna Inc. ( MRNA ) for the amount of $596146.88 on 2024-03-20
9.69% of Moderna Inc. ( MRNA ) is held by insiders, and 69.48% is held by institutions
Moderna Inc. ( MRNA ) went public on 2018-12-07
Other Moderna Inc. ( MRNA ) financial metrics:
Unlevered Free Cash Flow:-10648.00
Operating Margin:-109.89
Gross Profit Margin:-22.39
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-104.81
Buffet's Owners Earnings:689.77
Price to Owner's Earnings:90.17
About Moderna Inc. ( MRNA ) :
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
User Content from Tickernomics. Created by Luminus.

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.